Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199734561> ?p ?o ?g. }
- W3199734561 endingPage "2670" @default.
- W3199734561 startingPage "2660" @default.
- W3199734561 abstract "Review of the US and European literature indicates that most patients at high risk for atherosclerotic cardiovascular disease (ASCVD are not treated with high-intensity statins, despite strong clinical-trial evidence of maximal statin benefit. High-intensity statins are recommended for 2 categories of patients: those with ASCVD (secondary prevention) and high-risk patients without clinical ASCVD. Most patients with ASCVD are candidates for high-intensity statins, with a goal for low-density lipoprotein cholesterol reduction of 50% or greater. A subgroup of patients with ASCVD are at very high risk and can benefit by the addition of nonstatin drugs (ezetimibe with or without bile acid sequestrant or bempedoic acid and/or a proprotein convertase subtilisin/kexin type 9 inhibitor). High-risk primary prevention patients are those with severe hypercholesterolemia, diabetes with associated risk factors, and patients aged 40 to 75 years with a 10-year risk for ASCVD of 20% or greater. In patients with a 10-year risk of 7.5% to less than 20%, coronary artery calcium scoring is an option; if the coronary artery calcium score is 300 or more Agatston units, the patient can be up-classified to high risk. If high-intensity statin treatment is not tolerated in high-risk patients, a reasonable approach is to combine a moderate-intensity statin with ezetimibe. In very high-risk patients, proprotein convertase subtilisin/kexin type 9 inhibitors lower low-density lipoprotein cholesterol levels substantially and hence reduce risk as well." @default.
- W3199734561 created "2021-09-27" @default.
- W3199734561 creator A5000498350 @default.
- W3199734561 creator A5010041931 @default.
- W3199734561 creator A5017418373 @default.
- W3199734561 creator A5029257839 @default.
- W3199734561 creator A5051099314 @default.
- W3199734561 creator A5053163891 @default.
- W3199734561 creator A5056794714 @default.
- W3199734561 creator A5070148218 @default.
- W3199734561 creator A5081000352 @default.
- W3199734561 creator A5087095202 @default.
- W3199734561 creator A5088873680 @default.
- W3199734561 date "2021-10-01" @default.
- W3199734561 modified "2023-10-04" @default.
- W3199734561 title "High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better" @default.
- W3199734561 cites W121888607 @default.
- W3199734561 cites W1488616471 @default.
- W3199734561 cites W1520609538 @default.
- W3199734561 cites W1963966870 @default.
- W3199734561 cites W1964427420 @default.
- W3199734561 cites W1972517191 @default.
- W3199734561 cites W1982914740 @default.
- W3199734561 cites W1987507883 @default.
- W3199734561 cites W1988985578 @default.
- W3199734561 cites W1989492995 @default.
- W3199734561 cites W2009674945 @default.
- W3199734561 cites W2010033213 @default.
- W3199734561 cites W2013818621 @default.
- W3199734561 cites W2019513999 @default.
- W3199734561 cites W2021668065 @default.
- W3199734561 cites W2037883104 @default.
- W3199734561 cites W2040462758 @default.
- W3199734561 cites W2040982838 @default.
- W3199734561 cites W2059078444 @default.
- W3199734561 cites W2081034072 @default.
- W3199734561 cites W2100800328 @default.
- W3199734561 cites W2103108681 @default.
- W3199734561 cites W2105766576 @default.
- W3199734561 cites W2106285889 @default.
- W3199734561 cites W2134159541 @default.
- W3199734561 cites W2137983259 @default.
- W3199734561 cites W2139168645 @default.
- W3199734561 cites W2159449551 @default.
- W3199734561 cites W2164089346 @default.
- W3199734561 cites W2261871796 @default.
- W3199734561 cites W2292681792 @default.
- W3199734561 cites W2314193179 @default.
- W3199734561 cites W2396139649 @default.
- W3199734561 cites W2487995191 @default.
- W3199734561 cites W2511907480 @default.
- W3199734561 cites W2512341558 @default.
- W3199734561 cites W2537320940 @default.
- W3199734561 cites W2551364930 @default.
- W3199734561 cites W2596179513 @default.
- W3199734561 cites W2765432372 @default.
- W3199734561 cites W2795246664 @default.
- W3199734561 cites W2801486783 @default.
- W3199734561 cites W2802080707 @default.
- W3199734561 cites W2899669642 @default.
- W3199734561 cites W2899997727 @default.
- W3199734561 cites W2900112755 @default.
- W3199734561 cites W2911480094 @default.
- W3199734561 cites W2912784612 @default.
- W3199734561 cites W2914546434 @default.
- W3199734561 cites W2948233520 @default.
- W3199734561 cites W2965327853 @default.
- W3199734561 cites W2965468217 @default.
- W3199734561 cites W2967526684 @default.
- W3199734561 cites W2973595439 @default.
- W3199734561 cites W2987850771 @default.
- W3199734561 cites W3004830249 @default.
- W3199734561 cites W3013214255 @default.
- W3199734561 cites W3111275714 @default.
- W3199734561 cites W3183857127 @default.
- W3199734561 cites W4210329910 @default.
- W3199734561 cites W4230870013 @default.
- W3199734561 cites W4232386725 @default.
- W3199734561 cites W4232424184 @default.
- W3199734561 cites W4240735590 @default.
- W3199734561 cites W4384636240 @default.
- W3199734561 cites W52391516 @default.
- W3199734561 cites W60172896 @default.
- W3199734561 doi "https://doi.org/10.1016/j.mayocp.2021.02.032" @default.
- W3199734561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34531060" @default.
- W3199734561 hasPublicationYear "2021" @default.
- W3199734561 type Work @default.
- W3199734561 sameAs 3199734561 @default.
- W3199734561 citedByCount "5" @default.
- W3199734561 countsByYear W31997345612022 @default.
- W3199734561 countsByYear W31997345612023 @default.
- W3199734561 crossrefType "journal-article" @default.
- W3199734561 hasAuthorship W3199734561A5000498350 @default.
- W3199734561 hasAuthorship W3199734561A5010041931 @default.
- W3199734561 hasAuthorship W3199734561A5017418373 @default.
- W3199734561 hasAuthorship W3199734561A5029257839 @default.
- W3199734561 hasAuthorship W3199734561A5051099314 @default.
- W3199734561 hasAuthorship W3199734561A5053163891 @default.